Edible Cannabis, Blood THC Concentrations, and Implications for Impaired Driving Policy

• by José Ignacio Nazif-Munoz

• August 31, 2026

FDA approves oral dermatomyositis therapy

Phase 3 findings show improvements in physical function and skin disease activity.

• by Kathryn Wighton

• August 28, 2026

• 2 min

FDA monthly preview: Key September decisions to watch

Several FDA decisions across multiple specialties are expected this month.

• by Kathryn Wighton

• August 28, 2026

• 5 min

Positioning equity at the core of European dementia research: a pan-European co-produced perspective from the PANEUCARE consortium

• by Maria Isabel Cardona, Clarissa Giebel, Anthony Scerri, Anthea Innes, Ninoslav Mimica, Osman Kučuk, T. Rune Nielsen, Jūratė Macijauskienė, Birute Bartkevičiūtė, Carolien Smits, Carmel Geoghegan, Soraya Moradi-Bachiller, Anne Marie Rokstad, Iva Holmerova, Elżbieta Trypka, Ágnes Egervári, Raluca Sfetcu, Marija Taneska, Péter Hegedűs, Iryna Shevchenko, Svetlana Iloski, Thanos Chatzikostopoulos, Jochen René Thyrian

• August 31, 2026